Memory enhancement drugs market

Memory Enhancement Drugs Market, By Drug Class (Cholinesterase Inhibitors, Smart Drugs and Cognitive Enhancers (Nootropics) and Vitamins and Supplements and others), by Route of Administration (Oral, Topical, Injectable), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy ,Online Pharmacy, Drug Stores), by Application (Disease treatment, Athletic performance, Academic performance and others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East & Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Dec 2022
CMI5399
156 Pages
Excel & Pdf
Pharmaceutical

Summary

Nootropics, commonly referred to as cognitive enhancers, are medications that some people use in an effort to enhance their memory, mental alertness, focus, and energy levels. There are numerous varieties of nootropics. Some of these are pharmaceuticals that are intended to treat diseases like narcolepsy or excessive sleepiness as well as to help people with attention issues focus and pay attention better. However, some healthy individuals utilize these medications in an effort to enhance their cognitive function.

Global memory enhancement drugs market is estimated to be valued at US$ 7,912.1 million in 2022 and is expected to exhibit a CAGR of 5.5%during the forecast period (2022-2030).

Figure 1. Global Memory Enhancement Drugs Market Share (%) in Terms of Value, By Route of Administration

Global Memory Enhancement Drugs Market- Drivers

Increasing prevalence of aging population is expected to drive the global memory enhancement drugs market growth over the forecast period. For instance, According to an article published on March 2021, on Alzheimer’s Association, estimated that 6.2 million Americans age 65 and older are living with Alzheimer's dementia.

Increasing prevalence of neurological disorders are expected to drive the market growth during the forecast period. For instance, according to Neurological Alliance Report published on March 2019, there are an estimated 14.7 million neurological cases, equating to at least 1 in 6 people living with one or more neurological conditions.

Memory Enhancement Drugs Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 7,912.1 Mn
Historical Data for:	2017-2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.5%	2030 Value Projection:	US$ 12,172.1 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Drug Class: Cholinesterase Inhibitors, Smart Drugs and Cognitive Enhancers (Nootropics), Vitamins and Supplements, Others By Route of Administration: Oral, Injectable, Topical By Application: Disease treatment, Athletic performance, Academic performance, Others By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:	Pfizer Inc., UCB S.A., Takeda Pharmaceutical Company, Shire plc., Sanochemia Pharmazeutika AG, Allergan plc., Novartis AG, Alkem Laboratories Ltd., Paradigm Healthcare, Intas Pharmaceutical Ltd., Taurus Laboratories Pvt. Ltd.
Growth Drivers:	Increasing prevalence of aging population Increasing neurological disorders
Restraints & Challenges:	Side effects of the drugs

Figure 2. Global Memory Enhancement Drugs Market Share (%) in Terms of Value, By Region, 2022

Global Memory Enhancement Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

The supply of raw materials required for production of pharmaceuticals has been severely disrupted due to the forced quarantine and lack of labor during the COVID-19 pandemic. As the link between regional warehouses is not smooth, transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has negatively affected the supply chain of the global memory enhancement drugs market. Thus, the COVID-19 pandemic is expected to have a negative impact on supply chain of memory enhancement drugs market.

According to an article published by the Exploratory Research in Clinical and Social Pharmacy journal in June 2021, a study was carried out to evaluate the impact of COVID-19 on pharmaceutical systems and supply chain in resource-limited countries in Sub-Saharan countries such as Namibia. This study revealed negative impact on availability and access of essential drugs, sanitation and hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs, which is attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs.

For instance, according to a review article published by the European Pharmaceutical Review Journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.

Global Memory Enhancement Drugs Market - Restraint

The major factor that hinder the growth of global memory enhancement drugs market includes side effects like sleeplessness, hypertension and weight loss. Long term use of memory enhancement drugs can cause adverse effects like hypertension, chest pain, fever and etc. For instance, according to data published on June 2022, on Drugs.com, which is an online pharmaceutical encyclopedia that provides drug information for consumers and healthcare professionals, stated that long term of Ritalin, which is a memory enhancer drug can cause heart attack, insomnia, and hypertension.

Key Players

Key players operating in global memory enhancement drugs market include Pfizer Inc., UCB S.A., Takeda Pharmaceutical Company, Shire plc. Sanochemia Pharmazeutika AG, Allergan plc., Novartis AG, Alkem Laboratories Ltd., Paradigm Healthcare, Intas Pharmaceutical Ltd., Taurus Laboratories Pvt. Ltd.

Table of Content

Table of Contents

*Browse 27 market data tables and 31 figures on "Global Memory Enhancement Drugs Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global memory enhancement drugs market during the forecast period (2022-2030)?

The Global memory enhancement drugs market size is estimated to be valued at US$ 7,912.1 million in 2022 and is expected to exhibit a CAGR of 5.5% between 2022 and 2030

What are the major factors driving the market growth?

Factors such as increasing prevalence of aging population and increasing neurological disorders are expected to drive the market.

Which is the leading drug class segment in the market?

Smart Drugs and Cognitive Enhancers (Nootropics) segment is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include side effects of the drugs.

Which are the major players operating in market?

Major players operating in the market include Pfizer Inc., UCB S.A., Takeda Pharmaceutical Company, Shire plc. Sanochemia Pharmazeutika AG, Allergan plc., Novartis AG, Alkem Laboratories Ltd., Paradigm Healthcare, Intas Pharmaceutical Ltd., Taurus Laboratories Pvt. Ltd.